❉ Buffybot wonderful businesses, fair prices

← back

MTD Mettler Toledo

pharma · 2026-09-28

N/A
too hard · 94
Owner-earnings value$531.30
Price$1,511.64
Margin of safety -64.9%

Quality gate · 94/100

Returns on capital 30/30
Consistency 21.5/22
Margins / pricing power 15.3/16
Balance sheet 11.4/16
Cash conversion 9.9/10
Capital allocation 5.8/6

⚠ negative book equity

Median ROIC45.4%
Gross margin60.3%
Net debt / EBITDA1.6x
FCF conversion98%
Share count / yr-2.8%
Profitable years4/4

Moat & management

Owner-earnings inputs

Owner earnings (TTM)863.97M
Owner-earnings yield2.9%
Free-cash-flow yield2.9%
Growth used (normalized)0.9%
Market-implied growth (reverse DCF)25.0%
Terminal growth3.0%
Discount rate (hurdle)10.7%

Projected owner earnings

YrOwner earningsGrowthPV
1871.74M 0.9%787.66M
2881.61M 1.1%719.76M
3893.65M 1.4%659.22M
4907.95M 1.6%605.17M
5924.59M 1.8%556.83M
6943.69M 2.1%513.52M
7965.40M 2.3%474.66M
8989.85M 2.5%439.75M
91.02B 2.8%408.33M
101.05B 3.0%380.02M

Recent news

score · 8 articles

  • Mettler Toledo International (MTD), Why Is It Getting Fresh Attention?
  • 1 S&P 500 Stock Worth Your Attention and 2 We Ignore
  • What Makes Mettler-Toledo International (MTD) an Attractive Bet?
  • 2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds
  • Is Mettler-Toledo Stock Underperforming the Nasdaq?
  • Research Tools & Consumables Stocks Q2 Teardown: Mettler-Toledo (NYSE:MTD) Vs The Rest
  • Redburn starts Mettler-Toledo at Sell, sees valuation outpacing growth
  • Do Wall Street Analysts Like Mettler-Toledo Stock?

⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~25%/yr owner-earnings growth over 10y (reverse DCF); model credits 1%.

History

DateQualityPriceValueMoSRating
2026-09-28 94 $1,511.64 $531.30 -64.9% N/A
2026-08-25 94 $1,398.89 $564.86 -59.6% N/A
2026-07-23 94 $1,285.90 $511.29 -60.2% N/A
2026-07-02 94 $1,300.38 $518.40 -60.1% N/A
2026-06-25 94 $1,203.18 $523.67 -56.5% N/A
2026-06-23 94 $1,156.64 $517.12 -55.3% N/A